Gl261-luc Cells
Gl261-luc Cells - Related Videos
02:25
An Assay for Analyzing Test β-Glucan as an Immunotherapy Strategy against Brain Cancer Cells
0 Views •
2025
This video demonstrates an in vitro assay utilizing β-glucans to activate microglial cells for the production of superoxide radicals, a reactive oxygen species. In brain cancer cells, the generated reactive oxidants actively suppress tumor cell proliferation and induce cell death.
02:44
Luciferase-Based Assay to Evaluate Antiviral Compounds in Human Embryonic Kidney Cells
0 Views •
2026
Source: Lucas-Hourani, M. et.al., High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses. J. Vis. Exp. (2014)This video shows a luciferase-based antiviral assay in human embryonic kidney cells infected with recombinant measles virus. It shows that serially diluted test compounds inhibit viral replication, leading to lower luminescence in a dose-dependent manner while maintaining host cell viability.
15:42
Xenotransplantation of Human Stem Cells into the Chicken Embryo
0 Views •
Cited by 31 •
2010
In this paper we present a method for transplanting human stem cells into various regions of the central nervous system of the chicken embryo. This provides an in vivo model for assessing the proliferation and differentiation of various types of human stem cells in embryonic tissue environments.
09:23
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
0 Views •
Cited by 19 •
2016
Understanding the malignant behavior of cancer requires creating accurate models of how tumor cells interact with components of the tumor microenvironment, such as macrophages. Here we describe two methods to study glioblastoma cell interaction with tumor associated macrophages and microglia where the effect on glioblastoma invasion is assessed.
09:17
Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
0 Views •
Cited by 13 •
2016
GL261 glioma cells provide a useful immunocompetent animal model of glioblastoma. The goals of this protocol are to demonstrate proper techniques for monitoring intracranial tumor growth using in vivo bioluminescence imaging, and to verify the utility of luciferase-modified GL261 cells for studying tumor immunology and immunotherapeutic approaches for treating glioblastoma.
FAQs
Light is generated by the luciferase reaction after the luciferin substrate is administered. Gl261-luc cells carry the luciferase activity, while luciferin supplies the substrate for an enzyme-catalyzed reaction that produces detectable light. Because the signal can be measured in living animals, investigators can use it to visualize changes in tumor burden during an experiment.
Repeated imaging turns tumor assessment into a longitudinal measurement rather than a single endpoint. By observing bioluminescent output at multiple time points, researchers can follow disease development in the same living animal and examine how tumor burden changes during a study. This time-resolved view is especially useful when evaluating whether a treatment alters progression.
Bioluminescence imaging provides a noninvasive readout of tumor burden, whereas tissue collection requires removing biological material for assessment. With Gl261-luc cells, investigators can obtain repeated measurements from living animals and reserve tissue collection for selected study points. This reduces the need for repeated sampling and helps preserve longitudinal observation of disease development.
The workflow begins with intracranial implantation of the cells in a living animal. Researchers then administer the luciferin substrate so the luciferase reaction can generate detectable light. Imaging provides a measure of tumor burden, and repeated sessions allow disease development or treatment response to be followed over time.
In medicine, this model can be used to study glioblastoma biology, tumor progression, immune responses, and therapeutic efficacy. These areas let investigators examine disease development in living animals while tracking changes through bioluminescence. The resulting longitudinal measurements support preclinical research on how tumors develop and how treatments perform during a study.
A treatment study can use serial bioluminescence measurements as an outcome for tracking tumor burden. Measurements collected across time allow investigators to examine whether disease development changes during therapy. Because the readout is obtained noninvasively in living animals, repeated observation can reduce reliance on repeated tissue collection and support longitudinal assessment of therapeutic efficacy.